Protein Associated with Disease: what is next in research? @mansoor_steven @OHSUNews #P2X7receptor

Protein Associated with Disease: what is next in research? @mansoor_steven @OHSUNews #P2X7receptor

OHSU

1 month
19 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Steven Mansoor, MD @mansoor_steven of @OHSUSOM describes what is next and how this protein associated with many disease is visualized for the first time will affect clinicians today.

__________

New drugs can be motivated by understanding how receptors of P2X7 proteins function. 

Scientists first noticed how a protein associated with various health issues functions at the molecular level.

The breakthrough, that one day could inspire new drugs to treat inflammation, coronary artery disease, leukemia, multiple sclerosis, and more, has been published today in the Cell journal.

Research assistant at Oregon Health & Science University Alanna McCarthy, B.S., and scientist at OHSU Steven Mansoor, M.D., Ph.D., used cryoelectron microscopy to obtain a protein receptor's 3D structure and observe its inner working. The protein receptor they studied is a protein of the cell membrane that enables electrically charged particles of sodium and calcium to enter and cause changes in a cell.

They specifically studied the P2X7 receptor, a subtype associated with inflammation of the ligand-gated ion channel P2X family, plaque buildup in arteries, metastasis of cancer, neurological conditions, and more.

P2X7 is unique because its channel remains open indefinitely once it is activated, allowing continuously charged particles to enter a cell and initiate the inflammation signaling pathways, ultimately resulting in cell death. These signaling activity may contribute to the receptor-related long list of ailments.

Unlike previous efforts to image the P2X7 receptor, they were able to capture the protein receptor in its entirety through the cryo-EM imaging approach of the team.

This helped them to imagine the receptor sections inside the cell that were sitting. As a result, they can specifically analyze how fatty acid molecules called palmitoyl groups change these parts. When these groups were eliminated by Mansoor and his colleagues, they found that the receptor was no longer open indefinitely, shutting down their ability to trigger signaling. He also found suddenly that a guanosine nucleotide inside the cell was bound to P2X7.

Read here: https://www.oncologytube.com/video/first-fully-visualized-protein-associated-with-many-diseases

Up Next Autoplay
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
admin 6 hours
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 12 hours
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 12 hours
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 13 hours
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 13 hours
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 13 hours
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
1 Views
ash 1 day
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 1 day
Brentuximab Vedotin with Chemotherapy #ASH19
Brentuximab Vedotin with Chemotherapy #ASH19
Category: Chronic Myelogenous Leukemia
0 Views
ash 1 day
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
4 Views
ash 1 day